SLC5A2 and type 2 diabetes mellitus: In 2013, canagliflozin became the first sodium glucose co-transporter 2 (SGLT2) inhibitor approved by the US Food and Drug Administration (FDA) for reducing blood glucose in patients with type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise [1].